Lithium, a well-established therapeutic option for the management of bipolar disorder and major depression, has also been regarded as a neuroprotective agent and a candidate drug for disease-modification in certain neurodegenerative disorders like e.g. Alzheimer's disease.
Lithium inhibits the phosphorylation of glycogen-synthase-kinase 3-alpha and -beta (GSK3A and GSK3B), which are related to amyloid precursor protein processing and tau hyperphosphorylation in pathological conditions, respectively.
Microdose lithium treatment stabilizes the cognitive impairment in AD patients.
CIDeRplus
List all interactions
Display Graph